ENTOD launches COLLADERM transdermal collagen gel at DERMACON 2026
ENTOD Pharmaceuticals has launched COLLADERM, a transdermal collagen gel serum for regenerative skincare, at DERMACON 2026, the annual conference of the Indian Association of Dermatologists, Venereologists & Leprologists. Developed using AI-driven bio-engineering and optimised for Indian skin biology and climate, the product is being positioned as a prescription-led gel serum available through specialist dermatologist clinics.
Advancing Transdermal Collagen Delivery
COLLADERM incorporates a bio-engineered collagen system and a liposomal transdermal delivery platform designed to improve penetration and cellular uptake compared with conventional topical formats. The formulation also includes hyaluronic acid, glycerin, and vitamin C to support hydration and collagen activation, aiming to address limitations associated with oral or injectable collagen options.
India–UK Collaboration and Market Strategy
The product has been manufactured in India through an India–UK technology transfer collaboration and aligns with the Make in India initiative. ENTOD stated that the launch reflects its strategy to expand specialty healthcare offerings by integrating global research, formulation engineering and dermatologist-led skincare solutions.
Accelerate Your Launch Strategy
Planning a market entry or navigating complex regulations? Our healthcare strategists are ready to support your next milestone with precision and speed.
Speak to Our Experts